Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI) -- Ignore unavailable to you. Want to Upgrade?

To: Steven Messina,L.M.T. who wrote (221)	10/30/1997 1:26:00 PM
From: Deca Row	Respond to of 354

dear Mr. Gury explain to me why serologicals plasma sales increased soooo much? SEROLOGICALS REPORTS RECORD THIRD QUARTER RESULTS EARNINGS PER SHARE UP 33% TO $0.20 ATLANTA--(BUSINESS WIRE)--Oct. 27, 1997--Serologicals Corporation (Nasdaq/NM: SERO) today reported record quarterly sales and earnings for the quarter ended September 28, 1997. Net income for the third quarter increased 46% to $3.2 million compared with $2.2 million in the year-earlier period, and earnings per share rose 33% to $0.20 on 16.0 million shares outstanding versus $0.15 on 15.0 million shares outstanding. Net sales for the quarter increased 68% to $26.6 million versus $15.8 million in the third quarter of 1996. The strong performance for the third quarter resulted in an increase in net income for the nine months ended September 28, 1997 to $8.7 million, up 46% from $6.0 million in the comparable period of 1996. Earnings per share for the nine months rose 36% to $0.57 on 15.5 million shares versus $0.42 on 14.1 million shares during the similar period of 1996. Year to date net sales increased 54% to $72.6 million from $47.3 million in the comparable year-earlier period. The higher average number of shares outstanding for the quarter and first nine months was due principally to the Company's private placement of common stock in September 1997 and the conversion of a note payable into common shares in April 1997. The weighted average shares outstanding and per share results in the year-earlier periods have been adjusted to reflect the 3-for-2 stock split that occurred in February 1997. ''Operations at existing centers and acquisitions both made solid contributions to our growth in revenues and earnings in the third quarter and thus far in 1997. While our industry is typically characterized by lower activity levels during the third quarter due to donor vacation schedules, we experienced strong production and shipping volumes, particularly in anti-D antibodies and our other therapeutic antibody product lines. Our third quarter was further highlighted by the successful private placement of 950,000 shares of common stock, the acquisition of two additional specialty antibody donor centers in September and, for the second consecutive year, being recognized by Forbes magazine as one of The 200 Best Small Companies in America. We are very pleased with the positive momentum in the Company's competitive position,'' remarked Harold J. Tenoso, Ph.D., president and chief executive officer. Tenoso added, ''Although a portion of the approximately $17.5 million raised through the private placement was used to fund our latest acquisition in September, this additional equity capital, in combination with a recent increase in our line of credit from $20 million to $35 million, has further strengthened our ability to fund future growth opportunities.'' Serologicals Corporation, headquartered in Atlanta, is a leading worldwide provider of specialty human antibody-based products and services to major healthcare companies. The Company's services, including donor recruitment, donor management and clinical testing services, enable the Company to provide value-added products that are used as the active ingredients in therapeutic products for the treatment and management of such medical indications as Rh incompatibility in newborns, rabies and hepatitis and in diagnostic products such as blood typing reagents and diagnostic test kits. This release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company's ability to fund future growth opportunities. These forward-looking statements are subject to certain risks, uncertainties and other factors, including the Company's ability to continue to successfully identify internal growth opportunities, to identify, acquire and integrate acquisition targets and changes in the market for the Company's products, which could cause actual results to differ materially . Additional information on factors that could potentially affect the Company or its financial results may be found in the Company's filings with the Securities and Exchange Commission. Serologicals is a registered trademark of Serologicals Royalty Company. SEROLOGICALS CORPORATION Financial Highlights (In thousands, except per share amounts) (Unaudited) CONDENSED CONSOLIDATED INCOME STATEMENT DATA Third Quarter and Nine Months Ended September 28, 1997 and September 29, 1996 Third Quarter Ended Nine Months Ended Sept. 28, Sept. 29, Sept. 28, Sept. 29, 1997 1996 1997 1996 Net sales $ 26,609 $ 15,819 $ 72,571 $ 47,259 Costs & expenses: Cost of sales $ 16,873 $ 9,177 $ 46,085 $ 27,686 Selling, general & administrative expenses 3,415 2,248 9,619 6,880 Product development expenses 474 556 1,474 1,686 Interest (income) expense, net (134) (76) (358) 297 Other expense 942 412 2,019 1,294 Net income $ 3,227 $ 2,208 $ 8,725 $ 5,968 Net income per common share-Primary $ 0.20 $ 0.15 $ 0.57 $ 0.42 Weighted average shares outstanding(1) 16,027 15,016 15,541 14,072 (1) Adjusted for the Company's 3:2 stock split effective February 28, 1997. CONDENSED CONSOLIDATED BALANCE SHEET DATA Sept. 28, Dec. 29, 1997 1996 Cash and cash equivalents $ 27,913 $ 21,232 Total assets 118,002 80,837 Total liabilities 19,086 12,954 Stockholders' equity 98,916 67,883 Contact: Serologicals, Atlanta Russell H. Plumb, 404/296-5595 More news for referenced ticker symbols: SERO, and related industries: medical.